Arca Biopharma | ABIO - Assets


Arca Biopharma reported $1.14B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 96.05B 409M Sep/2026
Arca Biopharma USD 1.14B 634.91M Jun/2026
Biogen USD 32.05B 32.5M Sep/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Capricor Therapeutics USD 368.74M 42.45M Jun/2026
Cipla INR 434.34B 9.38B Sep/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 138.36M 7.5M Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Cytokinetics USD 1.82B 99.77M Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Grifols EUR 23.15B 142.7M Dec/2025
Laboratory Of America USD 18.92B 392.3M Sep/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Otsuka Holdings JPY 4.32T 72.62B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026